Análisis de la acción Seres Therapeutics Inc (MCRB)MCRBSeres Therapeutics Inc

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Seres Therapeutics Inc is a good buy right now, primarily due to its recent financial turnaround, reporting a net income of $4.6 million in Q2 2026, which translates to $0.47 per share, a significant improvement from a net loss of $19.9 million in the same quarter last year. Additionally, the stock has shown a positive momentum with a 5-day change of +12.06% and an RSI of 66.737, indicating strong buying pressure. However, a key risk is the company's high forward P/E ratio of 10.82, which suggests that the stock may be overvalued if future earnings do not meet expectations.

9 analysts cover MCRB: 7 rate it Buy, 2 Hold and 0 Sell. The average price target is 22.00.